Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. (23rd September 2018)

• Record Type: Journal Article
• Authors: Reikvam, Håkon; Skavland, Jørn; Gullaksen, Stein-Erik; Hovland, Randi; Gedde-Dahl, Tobias; Bruserud, Øystein; Gjertsen, Bjørn Tore
• Other Names: Nakase Kazunori Academic Editor.
• Is Part Of: Case reports in hematology. Volume 2018(2018)
• Publication Date: 2018-09-23
• Subjects: Hematology -- Periodicals; Hematology -- Case studies -- Periodicals; Blood -- Diseases -- Periodicals; Hematology; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.15
• DOI: 10.1155/2018/2045985
• Languages: English
• ISSNs: 2090-6560

Abstract

Abstract : Chronic myeloid leukemia (CML) is a myeloproliferative disorder in which neoplastic cells exhibit the Philadelphia chromosome and the related oncoprotein BCR-ABL1 . Allogeneic stem cell transplantation (allo-SCT) was considered the first-line treatment for CML, before the introduction of tyrosine kinase inhibitors (TKIs). However, patients are at risk for relapse years after transplantation. We present a patient who relapsed 25 years after allo-SCT for chronic phase CML. Polymerase chain reaction (PCR) detected gradually evaluated levels of BCR-ABL1 transcripts, eventually leading to the diagnosis of relapsed disease. Additional mutational analyses did not reveal mutations in the BCR-ABL1 gene, or other cooperating mutations. The patient was successfully treated with imatinib 400 mg daily, leading to new molecular remission. The case presentation emphasizes the need for long-term follow-up of such patients and the potential benefit of initiating TKI treatment with early signs of relapse.